logo

Royality Med Pharmaceuticals

Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymed.com
mobile-logo

Our commitment

We are committed to developing and delivering transformative vaccines and antibodies, providing long-lasting immunity for millions of people, where the burden of disease is greatest. During the COVID-19 pandemic, we played an important role as part of a truly global effort to respond to a new and unprecedented challenge.1 We will continue to advance science in vaccines and immune therapies and work with partners to drive improvements in public health and ensure our science reaches millions more people.


Our focus areas


To achieve our ambition, we are optimising the potential of both vaccines and antibodies to ensure no patient is left behind. We are engineering next generation vaccines that have the potential to generate potent and long-lasting immune responses. At the same time, we are pioneering novel approaches to develop highly targeted, long-acting antibodies, optimised with our half-life extension technology.2 We focus on a range of pathogens, including SARS-CoV-2,3 influenza4 and RSV.5 ​


Complementary approach

Vaccines for active immunisation; antibodies for passive immunisation for those who can’t mount an immune response

Technologies

Innovative next-generation technologies for vaccines; accelerated human antibody discovery, long-acting, high-yield manufacturing for antibodies.

Pathogens

SAR-CoV-2, influenza, RSV & beyond​


I would like to learn about Royality Med’s Pharmaceuticals discoveries to treat genetic diseases.


YES, TELL ME MORE